Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Rheumatoid Arthritis
•
General Rheumatology
•
Primary Care
How do you approach treatment intensification in patients with RA and low disease activity but not in remission, considering the potential risks of increased immunosuppression?
Related Questions
Would you have concerns with continuing denosumab for much longer than the available ten year clinical safety trial data for an individual with renal insufficiency with persistent osteoporosis/history of compression fractures?
Do you continue PJP prophylaxis indefinitely in patients on rituximab maintenance therapy?
In what clinical situations do you consider azathioprine for treatment of inflammatory arthritis?
Is it better to give dose 2 of the mRNA 2024-2025 Covid-19 vaccine at month 2 or month 6 after dose 1 in moderately immunocompromised patients?
How do you manage transaminitis in a patient receiving TNF alpha inhibitors?
For patients who do not have access to biologic therapies, what are some csDMARD combination pearls or tips that you have that have particular efficacy in different rheumatologic diseases?
In a patient with a history of seropositive erosive RA who has undergone treatment for a periprosthetic joint infection and currently has an antibiotic spacer in place with clinical improvement, what is the appropriate timing and strategy for restarting DMARDs and/or biologic therapy to balance infection risk with RA disease control?
How do you approach the management of recurrent episcleritis in a patient with RA that is otherwise well-controlled?
How do you manage oral ulcers as a side effect from leflunomide?
How do you treat nocturnal leg cramps?
